Rheumatology treats musculoskeletal and autoimmune diseases, including arthritis, lupus, gout, and vasculitis.
Send us all your questions or requests, and our expert team will assist you.
Providing a clear overview and definition of polymyalgia rheumatica (PMR) is essential for patients and clinicians alike, especially for those traveling abroad for specialist care. PMR is an inflammatory disease that primarily affects adults over the age of 50, causing sudden onset of muscle pain and stiffness in the shoulders, neck, and hips. In Turkey, where Liv Hospital’s rheumatology department is based, the condition is diagnosed and managed with a multidisciplinary approach that aligns with international standards. Recent studies indicate that up to 20% of elderly patients presenting with unexplained musculoskeletal pain may have PMR, underscoring the need for accurate assessment.
This page offers an in‑depth look at the disease, covering its clinical presentation, diagnostic criteria, epidemiology, treatment options, and long‑term outlook. It is written for international patients who are considering Liv Hospital for evaluation and management, as well as for healthcare professionals seeking a concise reference. By the end of the article, readers will have a solid understanding of what polymyalgia rheumatica entails and how Liv Hospital can support a seamless treatment journey.
Patients with polymyalgia rheumatica typically experience a rapid onset of bilateral pain and stiffness, most pronounced in the following areas:
The stiffness is characteristically worse in the morning and may last for more than an hour, often improving with gentle movement. Systemic symptoms such as low‑grade fever, fatigue, weight loss, and a mild elevation in inflammatory markers are also common. Polymyalgia rheumatica rarely causes joint swelling, which helps distinguish it from rheumatoid arthritis.
Key clinical clues include:
Understanding these patterns is crucial for a timely overview and definition of the condition, enabling clinicians to initiate therapy promptly and reduce the risk of complications such as giant‑cell arteritis.
The diagnosis of polymyalgia rheumatica is primarily clinical, supported by laboratory and imaging studies that rule out mimicking diseases. The 2012 European League Against Rheumatism (EULAR) criteria remain the gold standard and include:
Key laboratory markers:
Imaging, such as ultrasound of the shoulders, may reveal bursitis or tenosynovitis, further supporting the diagnosis. In ambiguous cases, magnetic resonance imaging (MRI) can detect inflammation in the peri‑articular structures. A thorough overview and definition therefore integrates clinical judgment with targeted investigations, ensuring that patients receive appropriate therapy without unnecessary delays.
Polymyalgia rheumatica is one of the most common inflammatory rheumatic diseases in the elderly, with a prevalence ranging from 0.5% to 1% in populations over 50 years of age. Geographic variation exists; the condition is more frequent in Northern Europe and North America, but cases are regularly reported worldwide, including Turkey.
Identified risk factors include:
Age remains the strongest predictor; incidence rises sharply after 70 years. Understanding these epidemiologic trends helps clinicians at Liv Hospital anticipate disease patterns among international patients, many of whom may be retirees traveling for comprehensive care.
The cornerstone of therapy for polymyalgia rheumatica is low‑dose glucocorticoids, which provide rapid symptom relief. A typical regimen starts with prednisone 12‑20 mg daily, tapered gradually over 12‑24 months based on clinical response and inflammatory markers.
Adjunctive treatments and monitoring strategies include:
Physical therapy plays a supportive role, focusing on gentle range‑of‑motion exercises to maintain muscle strength and joint flexibility. At Liv Hospital, the multidisciplinary team coordinates medication management, physiotherapy, and nutritional counseling, ensuring a holistic approach that aligns with the patient’s cultural and linguistic needs.
With appropriate treatment, the majority of patients experience marked improvement within weeks and can achieve remission. However, up to 30% may experience relapses during steroid tapering, necessitating careful monitoring.
Long‑term follow‑up considerations:
Patients who develop giant‑cell arteritis require immediate high‑dose steroids and may need additional immunosuppressive therapy. Overall survival is comparable to age‑matched controls, but quality of life improves significantly when disease activity is controlled. A comprehensive overview and definition thus emphasizes not only acute management but also the importance of sustained surveillance.
Liv Hospital offers JCI‑accredited rheumatology services tailored for international patients. Our team combines expertise in inflammatory diseases with personalized care coordination, including interpreter services, airport transfers, and accommodation assistance. State‑of‑the‑art diagnostic facilities and a multidisciplinary approach ensure that patients receive accurate diagnosis, effective treatment, and seamless follow‑up—all within a compassionate, culturally sensitive environment.
Ready to take the next step in managing polymyalgia rheumatica? Contact Liv Hospital today to schedule a comprehensive evaluation and experience world‑class care designed for international patients.
Liv Hospital Ulus
Spec. MD. Yıldız Gonca Doğru
Physiotheraphy and Rehabilitation
Liv Hospital Vadistanbul
Spec. MD. Muhsin Doran
Physiotheraphy and Rehabilitation
Liv Hospital Bahçeşehir
Prof. MD. Nazife Berna Tander
Physiotheraphy
Liv Hospital Bahçeşehir
Spec. MD. Gürkan Yılmaz
Rheumatology
Liv Hospital Bahçeşehir
Spec. MD. Roya Soltanalizadeh
Physiotheraphy
Liv Hospital Bahçeşehir
Spec. MD. Sibel Ertürkler
Physiotheraphy
Liv Hospital Topkapı
Spec. MD. Nevzat Koca
Rheumatology
Liv Hospital Topkapı
Spec. MD. Orge Fatoş Demirtaş
Physiotheraphy and Rehabilitation
Liv Hospital Topkapı
Spec. MD. Turgay Demiray
Physiotheraphy and Rehabilitation
Liv Hospital Ankara
Assoc. Prof. MD. Ali Erhan Özdemirel
Rheumatology (Physical Therapy)
Liv Hospital Ankara
Prof. MD. Haşim Çakırbay
Physiotheraphy and Rehabilitation
Liv Hospital Ankara
Spec. MD. Beril Özturan
Physiotheraphy and Rehabilitation
Liv Hospital Gaziantep
Spec. MD. Kasım Osmanoğlu
Physiotheraphy
Liv Hospital Gaziantep
Spec. MD. Başak Öğüt Perktaş
Physiotheraphy
Liv Hospital Gaziantep
Spec. MD. Hasan Kılıç
Rheumatology
Liv Hospital Samsun
Prof. MD. Mehmet Sayarlıoğlu
Rheumatology
Liv Bona Dea Hospital Bakü
MD. ŞAİQ MAHMUDOV
Physiotheraphy
Liv Bona Dea Hospital Bakü
Spec. MD. VEFA QULİYEVA
Pediatric Rheumatology
Liv Bona Dea Hospital Bakü
Spec. MD. Nümuna Aliyeva
Rheumatology
Liv Bona Dea Hospital Bakü
Spec. MD. ZÖHRE HAŞIMOVA
Physiotheraphy
Spec. MD. Şaig Mahmudov
Physiotheraphy and Rehabilitation
Liv Hospital Ulus + Liv Hospital Bahçeşehir
Prof. MD. Şenol Kobak
Rheumatology
Send us all your questions or requests, and our expert team will assist you.
Patients with polymyalgia rheumatica typically report rapid onset of aching in the shoulder girdle, upper back, neck, and hip region. Morning stiffness can exceed an hour and improves with gentle movement. Systemic features such as low‑grade fever, fatigue, weight loss, and elevated inflammatory markers are common, while joint swelling is usually absent, helping to differentiate PMR from rheumatoid arthritis. The pattern of pain and stiffness, especially in individuals over 50, is a key clinical clue. Recognizing these symptoms early allows prompt initiation of therapy, reducing the risk of complications like giant‑cell arteritis. The disease course varies, but most patients experience significant relief within weeks of treatment. Ongoing monitoring is essential to detect relapses or side effects of therapy.
Polymyalgia rheumatica is diagnosed based on age (≥50 years), bilateral shoulder pain, morning stiffness lasting ≥45 minutes, and elevated acute‑phase reactants (ESR/CRP). The 2012 European League Against Rheumatism (EULAR) criteria serve as the gold standard. Laboratory tests help rule out mimicking diseases; typical findings include high ESR, high CRP, mild anemia, and negative rheumatoid factor or anti‑CCP antibodies. Imaging such as shoulder ultrasound may reveal bursitis or tenosynovitis, and MRI can detect peri‑articular inflammation when the diagnosis is uncertain. Exclusion of alternative diagnoses, like rheumatoid arthritis or infection, is essential. A rapid response to low‑dose glucocorticoids (improvement within 48‑72 hours) further supports the diagnosis. Clinicians combine these elements to reach a confident diagnosis without unnecessary invasive procedures.
The most informative laboratory markers for polymyalgia rheumatica are the erythrocyte sedimentation rate (ESR) and C‑reactive protein (CRP), both typically markedly elevated (ESR often >40 mm/h, CRP >10 mg/L). A complete blood count may show mild anemia of chronic disease. Autoantibody panels, such as rheumatoid factor (RF) and anti‑cyclic citrullinated peptide (anti‑CCP), are usually negative, helping differentiate PMR from rheumatoid arthritis. Additional tests like liver function, renal profile, and glucose may be ordered to establish a baseline before initiating steroid therapy. While no single test is diagnostic, the pattern of elevated inflammatory markers together with clinical features strongly supports PMR.
The first‑line treatment for PMR is oral glucocorticoids, most commonly prednisone at an initial dose of 12‑20 mg per day. Patients typically experience rapid symptom relief within days to weeks. The dose is gradually tapered based on clinical response and normalization of ESR/CRP, with the tapering period ranging from 12 to 24 months. Adjunctive measures include calcium and vitamin D supplementation, bisphosphonates for osteoporosis prevention, and monitoring of blood glucose and blood pressure due to steroid side effects. In refractory cases or when long‑term steroid exposure is undesirable, steroid‑sparing agents such as methotrexate or tocilizumab may be added. Physical therapy is encouraged to maintain mobility and muscle strength. Regular follow‑up ensures the balance between disease control and minimizing adverse effects.
Giant‑cell arteritis (GCA) occurs in up to 20 % of patients with polymyalgia rheumatica and can lead to serious complications such as vision loss. Clinicians should be alert for symptoms like new‑onset severe headache, scalp tenderness, jaw claudication during chewing, and sudden visual changes. Elevated ESR/CRP may be markedly higher in GCA, but normal values do not exclude it. If GCA is suspected, high‑dose intravenous or oral glucocorticoids are started immediately, often at 40‑60 mg prednisone daily, before confirmatory temporal artery biopsy. Prompt treatment reduces the risk of irreversible blindness. Patients with PMR should be educated to report any of these warning signs promptly.
BlogOrthopedicsFeb 19, 2026Rotator cuff injuries are common, causing pain and limiting movement. Rowing machines are being used in reh...
BlogDentistryDec 29, 2025Oral cancer, also known as mouth cancer, can affect different parts of the mouth. This includes the lips, g...
BlogEndocrinologyDec 29, 2025Millions of people worldwide take statins daily to manage cholesterol and reduce heart disease risk. Many r...
BlogDentistryDec 29, 2025It’s vital to spot the early signs of throat cancer to get the best treatment. At Liv Hospital, we st...
BlogPediatricsMar 27, 2026As the world’s population gets older, bone marrow failure syndromes like myelodysplastic syndrome (MD...
BlogCardiologyFeb 19, 2026Imagine feeling extreme pain with your first bite of food. This is what some patients face after carotid ar...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 174 26 75